Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 12/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6881731 | 0.91 | DRD4 (0.52) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| SCHEMBL6883746 | 0.90 | DRD4 (0.51) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| SCHEMBL6878954 | 0.87 | DRD4 (0.52) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| SCHEMBL6881816 | 0.87 | ALDH1A1 (0.50) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| SCHEMBL6883221 | 0.85 | ALDH1A1 (0.50) | DRD4KDM4EALDH1A1HTTGAA | |
| SCHEMBL6880423 | 0.84 | DRD4 (0.54) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| SCHEMBL6880280 | 0.83 | HPGD (0.67) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| SCHEMBL6881533 | 0.81 | DRD4 (0.49) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| SCHEMBL19558148 | 0.79 | HTT (0.66) | DRD4DRD2KDM4EALDH1A1CYP3A4 | |
| SCHEMBL6874013 | 0.78 | DRD4 (0.56) | DRD4DRD2KDM4EALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040166137-A1 | Hetero-substituted benzimidazole compounds and antiviral uses thereof | TRIMERIS, INC. | 2004-08-26 | — | — | US | disclosed |
| WO-2004043913-A2 | HETERO-SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND ANTIVIRAL USES THEREOF | TRIMERIS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040166137-A1 | Hetero-substituted benzimidazole compounds and antiviral uses thereof | MAVS, TIMM13, TIMM10 | DRD4 1550/4885DRD2 2651/4885KDM4E 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.